PROCESSO PARA A PREPARACAO DE 14BETA-H-, 14- E 15-ENO-11BETA-ARIL-4-ESTRENOS E DE COMPOSICOES FARMACEUTICAS QUE OS CONTEM

PCT No. PCT/EP91/02494 Sec. 371 Date Jun. 22, 1993 Sec. 102(e) Date Nov. 1, 1993 PCT Filed Dec. 21, 1991 PCT Pub. No. WO92/11278 PCT Pub. Date Jul. 9, 1992.Novel compounds of the general formula I (I) and the pharmacologically tolerable addition salts thereof with acids are described, in which eithe...

Full description

Saved in:
Bibliographic Details
Main Authors WOLFGANG SCHWEDE, ECKHARD OTTOW, GUNFER NEEF, ARWED CLEVE, HORTS MICHNA, KRZYSZTOF CHWALISZ, ULRIKE FUHRMANN
Format Patent
LanguagePortuguese
Published 30.06.1999
Edition6
Subjects
CHEMISTRY
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
STEROIDS
Online AccessGet full text

Cover

More Information
Summary:PCT No. PCT/EP91/02494 Sec. 371 Date Jun. 22, 1993 Sec. 102(e) Date Nov. 1, 1993 PCT Filed Dec. 21, 1991 PCT Pub. No. WO92/11278 PCT Pub. Date Jul. 9, 1992.Novel compounds of the general formula I (I) and the pharmacologically tolerable addition salts thereof with acids are described, in which either Ia) R11 represents a hydrogen atom in the beta -configuration and each of R12 and R13 represents a hydrogen atom, or Ib) R11 represents a hydrogen atom in the beta -configuration and R12 and R13 together represent a second bond, or Ic) R11 and R12 together represent a second bond and R13 represents a hydrogen atom, or Id) R11 represents a hydrogen atom in the alpha -configuration and R12 and R13 together represent a second bond, and in Ia), Ib), Ic) or Id) X represents an oxygen atom, the hydroxyimino grouping >N DIFFERENCE OH or two hydrogen atoms, R1 represents a hydrogen atom or a methyl group, R2 represents a hydroxy group, a C1-C10-alkoxy group or a C1-C10-acyloxy group, and R3 and R4 have the meanings customary for competitive progesterone antagonists specified in the description. The invention relates also to processes for the preparation of the novel compounds, to pharmaceutical compositions containing those compounds, to their use for the manufacture of medicaments, and to the novel intermediates required for the process. The novel compounds have a strong affinity for the gestagen receptor and exhibit pronounced antigestagenic and also antiglucocorticoid, antimineralocorticoid and antiandrogenic properties.
Bibliography:Application Number: PT19910099910